EM Pharmaceuticals is developing a pipeline of highly novel in vivo c-Met targeting theragnostic agents that will alter the landscape of precision medicine.

Using its proprietary platform technology, EM Imaging is developing clinical stage highly novel in vivo c-Met targeting optical imaging agents for early cancer detection and surgery guidance.